Perioperative use of anti-EGFR antibodies in resectable and potentially resectable liver metastases
https://doi.org/10.18027/2224-5057-2019-9-4-70-74
Abstract
The radical resection of all visible disease manifestations can significantly improve the prognosis of patients with metastatic colorectal cancer, however, complete metastasectomy is initially possible only in a small proportion of patients, with many of them subsequently developing relapse. Aiming to increase the number of patients subject to radical intervention and to reduce the recurrence risk, preoperative chemotherapy (with or without subsequent adjuvant treatment) is widely used in routine practice. In the hope of increasing immediate effectiveness (increasing the proportion of patients subject to R0 resection) and the long-term results of treatment, preoperative chemotherapy is often accompanied with biological agents (anti-EGFR and anti-VEGF monoclonal antibodies) continued after surgery in some cases. However, despite the evidence of increased resectability, the impact of this approach on long-term treatment outcomes has not yet been determined. The analysis of recent studies in this area doubts the safety of perioperative use of anti-EGFR antibodies in patients with potentially curable metastatic colorectal cancer.
About the Author
N. V. Zhukov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology;
N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Nikolay V. Zhukov, MD, PhD, DSc, Head of the Department of Interdisciplinary Oncology; Associate Professor, Department of Oncology, Hematology and Radiation Therapy
Moscow
References
1. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and metaanalysis of prognostic factors. Clin Epidemiol 2012; 4: 283 – 301.
2. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13 (10):1261 – 1268. doi:10.1245 / s10434‑006‑9023‑y
3. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised c ontrolled trial. Lancet 2008;371: 1007 – 16
4. Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).Ann Surg 2012; 255: 534 – 39.
5. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11 (1):38 – 47. doi:10.1016 / S1470–2045 (09) 70330 – 4
6. Petrelli, F., & Barni, S. (2012). Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. International journal of colorectal disease, 27 (8), 997 – 1004.
7. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC – C Study. J Clin Oncol. 2007;25 (30):4779 – 4786. doi:10.1200 / JCO. 2007.11.3357
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350 (23):2335 – 2342. doi:10.1056 / NEJMoa032691
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350 (23):2335 – 2342. doi:10.1056 / NEJMoa032691
10. Pietrantonio F, Cremolini C, Petrelli F, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015;96 (1):156 – 166. doi:10.1016 / j. critrevonc. 2015.05.016
11. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and antiEGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26 (1):13 – 21. doi:10.1093 / annonc / mdu378
12. Bridgewater JA Pugh SA Maishman T et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020; (published online Jan 31) https://doi.org / 10.1016 / S1470–2045 (19) 30798 – 3
13. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014; 15: 601 – 11
14. Dahan L, Sadok A, Formento JL, Seitz JF, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158 (2):610 – 620. doi:10.1111 / j.1476 – 5381.2009.00341. x
15. Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14 (8):749 – 759. doi:10.1016 / S1470–2045 (13) 70163 – 3
16. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316 (5827):1039 – 1043. doi:10.1126 / science. 1141478
17. Taïeb J, Tabernero J, Mini E, et al. Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab in resected stage III colon cancer. Ann Oncol 2013; 31 (suppl): 3525 (abstr).
18. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307 (13):1383 – 1393. doi:10.1001 / jama. 2012.385
19. Gholami, S., & Grothey, A. (2020). EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?. The Lancet Oncology. Published: January 31, 2020DOI: https://doi.org / 10.1016 / S1470–2045 (20) 30003 – 6
Review
For citations:
Zhukov N.V. Perioperative use of anti-EGFR antibodies in resectable and potentially resectable liver metastases. Malignant tumours. 2019;9(4):70-74. (In Russ.) https://doi.org/10.18027/2224-5057-2019-9-4-70-74
Views:
753
Email this article 